Literature DB >> 2170681

Up regulation of the Epstein-Barr virus (EBV)-encoded membrane protein LMP in the Burkitt's lymphoma line Daudi after exposure to n-butyrate and after EBV superinfection.

B Contreras-Salazar1, B Ehlin-Henriksson, G Klein, M G Masucci.   

Abstract

The Burkitt's lymphoma line Daudi carries a nontransforming Epstein-Barr virus (EBV) strain that has a deletion in the BamHI WYH region of the genome coding for the EBV nuclear antigen 2 (EBNA-2). Daudi cells fail to express the EBV-encoded latent membrane protein (LMP) (D. Ghosh and E. Kieff, J. Virol. 64:1855-1858, 1990). We show that LMP expression can be up regulated by exposure to n-butyrate and by superinfection with the B95-8 (B virus)- and P3HR1 (P virus)-derived EBV strains. Two LMP polypeptides of 60 and 48 kilodaltons (kDa) were detected in immunoblots of Daudi cells that had been exposed to 3 mM n-butyrate for 24 h. The intensity of the 48-kDa LMP increased during 72 h, in parallel with the appearance of early antigen-positive cells. The 60-kDa LMP was expressed at a low level and remained constant. Superinfection of Daudi cells with B and P virus induced the 60-kDa LMP within 3 h. In addition, P virus induced the 48-kDa LMP at a low level. The B virus-encoded EBNA-2 and EBNA-5 were detected 12 h after superinfection. The B virus-encoded 63-kDa LMP was coexpressed with the endogenous LMP after 48 h. Inactivation of the virus by UV illumination abolished the expression of the B virus-encoded antigens but did not affect the induction of the endogenous LMP. The B-cell activation marker CD23 was up regulated by B virus superinfection but not by n-butyrate exposure. CD23 was also expressed at a higher level in a stable B virus-converted subline, E95A-Daudi, that was EBNA-2 positive and coexpressed the Daudi virus- and B virus-encoded LMP. The results suggest that LMP expression is regulated by the interaction of cellular and viral factors. Binding of the virus to its membrane receptor might be involved in the triggering of cellular control mechanisms. Viral gene products are not directly involved in this function but may contribute to create a permissive cellular environment for LMP expression.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2170681      PMCID: PMC248595          DOI: 10.1128/JVI.64.11.5441-5447.1990

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines.

Authors:  J Finke; M Rowe; B Kallin; I Ernberg; A Rosén; J Dillner; G Klein
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

2.  Different patterns of Epstein-Barr virus gene expression and of cytotoxic T-cell recognition in B-cell lines infected with transforming (B95.8) or nontransforming (P3HR1) virus strains.

Authors:  R J Murray; L S Young; A Calender; C D Gregory; M Rowe; G M Lenoir; A B Rickinson
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

3.  Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells.

Authors:  A Calender; M Billaud; J P Aubry; J Banchereau; M Vuillaume; G M Lenoir
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

4.  Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines.

Authors:  M G Masucci; S Torsteindottir; J Colombani; C Brautbar; E Klein; G Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

5.  The truncated form of the Epstein-Barr virus latent-infection membrane protein expressed in virus replication does not transform rodent fibroblasts.

Authors:  D Wang; D Liebowitz; E Kieff
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

6.  Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus.

Authors:  V R Baichwal; B Sugden
Journal:  Oncogene       Date:  1988-05       Impact factor: 9.867

Review 7.  The Epstein-Barr virus proteins.

Authors:  J Dillner; B Kallin
Journal:  Adv Cancer Res       Date:  1988       Impact factor: 6.242

8.  An Epstein-Barr virus transforming protein associates with vimentin in lymphocytes.

Authors:  D Liebowitz; R Kopan; E Fuchs; J Sample; E Kieff
Journal:  Mol Cell Biol       Date:  1987-07       Impact factor: 4.272

9.  Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma.

Authors:  R Fåhraeus; H L Fu; I Ernberg; J Finke; M Rowe; G Klein; K Falk; E Nilsson; M Yadav; P Busson
Journal:  Int J Cancer       Date:  1988-09-15       Impact factor: 7.396

10.  Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells.

Authors:  M Rowe; D T Rowe; C D Gregory; L S Young; P J Farrell; H Rupani; A B Rickinson
Journal:  EMBO J       Date:  1987-09       Impact factor: 11.598

View more
  14 in total

1.  Induction of Epstein-Barr virus latent membrane protein 1 by a lytic transactivator Rta.

Authors:  Yao Chang; Heng-Huan Lee; Shih-Shin Chang; Tsuey-Ying Hsu; Pei-Wen Wang; Yu-Sun Chang; Kenzo Takada; Ching-Hwa Tsai
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

2.  Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes.

Authors:  M Rowe; A L Lear; D Croom-Carter; A H Davies; A B Rickinson
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

3.  Epstein-Barr virus inhibits Kaposi's sarcoma-associated herpesvirus lytic replication in primary effusion lymphomas.

Authors:  Dongsheng Xu; Tricia Coleman; Jun Zhang; Ashley Fagot; Catherine Kotalik; Lingjun Zhao; Pankaj Trivedi; Clinton Jones; Luwen Zhang
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

4.  The herpes simplex virus type 1 latency-associated transcript promoter is activated through Ras and Raf by nerve growth factor and sodium butyrate in PC12 cells.

Authors:  D P Frazier; D Cox; E M Godshalk; P A Schaffer
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

5.  Bcl-XL, but not Bcl-2, can protect human B-lymphoma cell lines from parthenolide-induced apoptosis.

Authors:  Alan T Yeo; John A Porco; Thomas D Gilmore
Journal:  Cancer Lett       Date:  2011-12-06       Impact factor: 8.679

6.  Silencing of the Epstein-Barr virus latent membrane protein 1 gene by the Max-Mad1-mSin3A modulator of chromatin structure.

Authors:  A Sjöblom-Hallén; W Yang; A Jansson; L Rymo
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

7.  NF-kappaB down-regulates expression of the B-lymphoma marker CD10 through a miR-155/PU.1 pathway.

Authors:  Ryan C Thompson; Melanie Herscovitch; Ian Zhao; Tyler J Ford; Thomas D Gilmore
Journal:  J Biol Chem       Date:  2010-10-14       Impact factor: 5.157

8.  (-)-Epigallocatechin-3-gallate inhibition of Epstein-Barr virus spontaneous lytic infection involves downregulation of latent membrane protein 1.

Authors:  Sufang Liu; Hongde Li; Min Tang; Ya Cao
Journal:  Exp Ther Med       Date:  2017-11-13       Impact factor: 2.447

9.  n-Butyrate, a cell cycle blocker, inhibits the replication of polyomaviruses and papillomaviruses but not that of adenoviruses and herpesviruses.

Authors:  F F Shadan; L M Cowsert; L P Villarreal
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

10.  A Genome-Wide Epstein-Barr Virus Polyadenylation Map and Its Antisense RNA to EBNA.

Authors:  Vladimir Majerciak; Wenjing Yang; Jing Zheng; Jun Zhu; Zhi-Ming Zheng
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.